ULTRA-HIGH PERFORMANCE LASER ENGINE TECHNOLOGY
TruScan utilizes highly innovative laser technology, assuring supreme standards of performance and versatility with up to 10 times a higher life span than its competitors.
One of the TruScan greatest hidden features is its diffusion bonding laser cavity design, utilizing advanced coating elements that are applied to the laser optical components. This proprietary and patented technology maintains peak stability and durability under high stress conditions.
This is a vital advantage over contemporary pattern scanning systems, as laser delivery in sub-threshold or pattern scanning mode requires usage of the laser at high energy levels, forcing the laser to work at its maximum loads.
SUPERB ENERGY DISTRIBUTION ENHANCING TREATMENT OUTCOMES
The innovative laser technology and superb optical design of the TruScan assure accurate power delivery and precise energy density distribution across the treatment area in both single and pattern scanning mode.
It has been common practice for other pattern-scanning lasers to compromise their treatment speed by poor laser efficacy, creating a cumulative energy defect or delivering uneven energy within the treated (laser scanned) area. TruScan produces excellent spot size precision with accurate energy distribution across every spot size, regardless of the mode of operation.
The all-new digitally controlled instant-duty cycle circuitry allows for a quick laser energy feedback loop that monitors each shot, and instantly adjusts for stable output, enhancing treatment safety and clinical outcomes.
SUB-THRESHOLD PHOTOCOAGULATION IN SINGLE & PATTERN MODE
TruScan can be used in traditional continuous wavelength (CW) and sp-mode™ (sub-threshold photocoagulation) treatment modalities, allowing conventional and next-gen approach for effective management of retinal diseases and glaucoma.
The sp-mode™ is the latest evolution in LightMed laser photocoagulators, offering a promising approach to achieve optimum clinical outcomes while eliminating laser-induced thermal tissue damage and treatment side effects. This technology allows for a broader range of treatment choices. Ongoing studies demonstrate that this product is highly effective, and has the ability to treat disorders at a much earlier stage. It also has the possibility of repeatable treatment in retinal applications and glaucoma.
TruScan uniquely permits the use of its sub-threshold mode in single and pattern scanning treatment. This offers the possibility of enhancing the clinical efficacy of the tissue friendly procedure, as it generally does not produce a visible burn mark.
The sp-mode™ is not a replacement to conventional continuous wavelength (CW) photocoagulation, but a very variable complement.When added with the pattern scanning modality and multi-wavelength options, the TruScan becomes a very powerful tool for the most discerning physician.
sp-mode™ treatment has demonstrated great efficacy on a large number of clinical applications including:
~ Diabetic macular edema.
~ Macular edema secondary to retinal vein occlusion.
~ Proliferative and non proliferative diabetic retinopathy.
~ Sub-threshold laser trabeculoplasty.
~ Used to reduce intraocular pressure in primary open angle glaucoma. ~ Similar outcomes to conventional microsecond-width pulse laser trabeculoplasty.
sp-mode™ sub-threshold photocoagulation clinical highlights include:
~ Possibly of treatments in the macular region as due to fovea- friendly properties.
~ Photocoagulation is painless with a 10-fold safety margins increase compared to traditional CW laser photocoagulation.
~ More efficient treatment with reduced risk of post-op complications.
~ Less destruction of healthy tissue allowing for repeatable retinal and glaucoma treatment.
~ Can be used in very early stages of the disease improving visual outcomes and offering greater range of treatment options.
~ Stimulates the RPE to function better, and naturally releases the cytokines that modify the genetic expression and the production of VEGFs.
~ Demonstrating high efficacy as first mode of treatment in retinal disease.
~ Viable alternative or great adjunct to the intravitreal anti-VEGEF injection therapy.
FOUR CUSTOMIZABLE WAVELENGTH OPTIONS